NO985829L - Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av aterosklerose uten formÕlsbestemt strÕling av porfyrinderivatene - Google Patents

Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av aterosklerose uten formÕlsbestemt strÕling av porfyrinderivatene

Info

Publication number
NO985829L
NO985829L NO985829A NO985829A NO985829L NO 985829 L NO985829 L NO 985829L NO 985829 A NO985829 A NO 985829A NO 985829 A NO985829 A NO 985829A NO 985829 L NO985829 L NO 985829L
Authority
NO
Norway
Prior art keywords
treatment
development
green porphyrin
radiation
atherosclerosis
Prior art date
Application number
NO985829A
Other languages
English (en)
Norwegian (no)
Other versions
NO985829D0 (es
Inventor
Barbara Kelly
Julia Levy
Phillippe Maria Clota Margaron
Original Assignee
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc filed Critical Qlt Phototherapeutics Inc
Publication of NO985829D0 publication Critical patent/NO985829D0/no
Publication of NO985829L publication Critical patent/NO985829L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO985829A 1996-06-14 1998-12-11 Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av aterosklerose uten formÕlsbestemt strÕling av porfyrinderivatene NO985829L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/663,890 US5834503A (en) 1996-06-14 1996-06-14 Methods to treat arterial plaque
PCT/CA1997/000393 WO1997048393A1 (en) 1996-06-14 1997-06-05 Use of green porphyrins in the manufacture of a medicament in the treatment of atherosclerosis without purposeful irradiation of the porphyrin derivatives

Publications (2)

Publication Number Publication Date
NO985829D0 NO985829D0 (es) 1998-12-11
NO985829L true NO985829L (no) 1999-02-11

Family

ID=24663656

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985829A NO985829L (no) 1996-06-14 1998-12-11 Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av aterosklerose uten formÕlsbestemt strÕling av porfyrinderivatene

Country Status (13)

Country Link
US (2) US5834503A (es)
EP (1) EP0910371A1 (es)
JP (1) JP2000512300A (es)
KR (1) KR20000016656A (es)
CN (1) CN1101188C (es)
AR (1) AR008392A1 (es)
AU (1) AU714045B2 (es)
CA (1) CA2257564A1 (es)
HU (1) HUP0001063A3 (es)
NO (1) NO985829L (es)
NZ (1) NZ333236A (es)
TW (1) TW514527B (es)
WO (1) WO1997048393A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
US6331235B1 (en) * 1998-12-11 2001-12-18 The University Of British Columbia Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6609014B1 (en) * 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US20040229295A1 (en) * 1999-05-17 2004-11-18 Marchitto Kevin S. Activated delivery of biomolecules using electromagnetic energy
US20040208855A1 (en) * 1999-11-17 2004-10-21 Allison Beth Anne Use of PDT to inhibit intimal hyperplasia
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
US20030103995A1 (en) 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
DE60307545T2 (de) * 2002-06-21 2007-10-04 Adair, Edwin L., Castle Pines Village Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20080193376A1 (en) * 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
EP2309985B1 (en) 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US7968127B2 (en) * 2008-07-28 2011-06-28 Winslow David E Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
CN115054703B (zh) * 2022-06-30 2023-08-04 东南大学 具有近红外光响应性和靶向性的脂质体、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512762A (en) * 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5129396A (en) * 1988-11-10 1992-07-14 Arye Rosen Microwave aided balloon angioplasty with lumen measurement
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
CA2138124A1 (en) * 1992-06-24 1994-01-06 David D. Eveleth, Jr. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
ATE314845T1 (de) * 1993-07-29 2006-02-15 Us Health Verwendung von paclitaxel und seinen derivaten zur herstellung eines medikaments für die behandlung von restenose
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque

Also Published As

Publication number Publication date
KR20000016656A (ko) 2000-03-25
CN1101188C (zh) 2003-02-12
NO985829D0 (es) 1998-12-11
CN1222076A (zh) 1999-07-07
NZ333236A (en) 2000-06-23
JP2000512300A (ja) 2000-09-19
HUP0001063A3 (en) 2001-02-28
US6235767B1 (en) 2001-05-22
AU714045B2 (en) 1999-12-16
EP0910371A1 (en) 1999-04-28
TW514527B (en) 2002-12-21
AR008392A1 (es) 2000-01-19
CA2257564A1 (en) 1997-12-24
US5834503A (en) 1998-11-10
WO1997048393A1 (en) 1997-12-24
HUP0001063A2 (hu) 2000-09-28
AU2947097A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
NO985829L (no) Anvendelse av gr°nne porfyriner for fremstilling av et medikament for behandling av aterosklerose uten formÕlsbestemt strÕling av porfyrinderivatene
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
Tzischinsky et al. The importance of timing in melatonin administration in a blind man
ITMI912024A1 (it) Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
RS49918B (sr) Upotreba glp-1, ili analoga za lečenje infarkta miokarda
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
DK0563023T3 (da) Anvendelse af vævsfaktor pathway inhibitor til fremstilling af et medikament til anvendelse ved en fremgangsmåde til hæmnin
DK160460C (da) Insulinpraeparat til nasal eller rektal administration og anvendelse af et insulinderivat til fremstilling af praeparatet
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
RU95105973A (ru) Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза
NO20003313D0 (no) Terapeutiske midler
ITTO920303A1 (it) Composizione farmaceutica antiinfiammatoria
Halasz Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments)
KR910005858A (ko) 지방산 요법
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
Lemke et al. Alterations in the arrhythmogenic dose of epinephrine after xylazine or medetomidine administration in isoflurane-anesthetized dogs
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
Korkushko et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
NO863082D0 (no) Preparat for intramuskulaer injeksjon av legemidler, vitaminer eller vaksiner.
NO971043L (no) Anvendelse av IL-4 for potensering av kjemoterapeutiske midler
NO990283L (no) Formulering for behandling og/eller profylakse av demens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application